Table 2 of
Yousaf, Mol Vis 2011; 17:1153-1163. Table 2 of
Yousaf, Mol Vis 2011; 17:1153-1163.
Table 2. Genotype and allele frequency comparison of XPD (c.2298A>C [rs13181]) in controls and patients and with gender distribution.
| Genotype | Male+Female Controls (n=193) | Male+Female POAG (n=160) | p (z) | p (χ2) | OR (95% CI) | Male+Female PCAG (n=163) | p (z) | p (χ2) | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| AA | 92(48%) | 52(33%) | <0.005(2.89) | 0.01(8.75) | DM=1.89(1.23–2.92) p=0.005 RM=1.62(0.91–2.86) p>0.05 | 58(36%) | <0.05(2.3) | >0.05 (5.68) | DM=1.65(1.08–2.53) p<0.05 RM=1.52(0.86–2.69) p>0.05 |
| AC | 76(39%) | 77(48%) | >0.05(1.65) | 75(46%) | >0.05(1.26) | ||||
| CC | 25(13%) | 31(19%) | >0.05(1.64) | 30(18%) | >0.05(1.42) | ||||
| Allele | Male+Female Controls | Male+Female POAG | p (χ2) | OR (95% CI) | Male+Female PCAG | p (χ2) | OR (95% CI) | ||
| A | 260(55%) | 181(57%) | <0.005(8.7) | 1.59(1.17–2.15) p<0.005 | 191(59%) | 1.46(1.07–1.98) p<0.05 | |||
| C | 126(33%) | 139(43%) | 135(41%) | <0.05(5.85) | |||||
| Genotype | Male Controls (n=101) | Male POAG (n=80) | p (z) | p (χ2) | OR (95% CI) | Male PCAG (n=81) | p (z) | p (χ2) | OR (95% CI) |
| AA | 56(55%) | 27(34%) | <0.005(2.91) | <0.005(12.1) | DM=2.44(1.33–4.47) p<0.005 RM=3.62(1.45–9.01) p<0.01 | 33(41%) | 0.05(1.97) | >0.05 (4.71) | DM=1.81(1.00–3.26) p=0.05 RM=2.1(0.8–5.55) p>0.05 |
| AC | 38(38%) | 36(45%) | >0.05(1.00) | 37(46%) | >0.05(1.1) | ||||
| CC | 7(7%) | 17(21%) | 0.005(2.82) | 11(13%) | >0.05(1.49) | ||||
| Allele | Male Controls | Male POAG | p (χ2) | OR (95% CI) | Male PCAG | p (χ2) | OR (95% CI) | ||
| A | 150(74%) | 90(56%) | <0.001(12.96) | 2.24(1.44–3.49) p<0.001 | 103(64%) | <0.05(4.84) | 1.65(1.06–2.6) p<0.05 | ||
| C | 52(26%) | 70(44%) | 59(36%) | ||||||
| Genotype | Female Controls (n=92) | Female POAG (n=80) | p (z) | p (χ2) | OR (95% CI) | Female PCAG (n=82) | p (z) | p (χ2) | OR (95% CI) |
| AA | 36(39%) | 25(31%) | >0.05(1.08) | >0.05(1.77) | DM=1.41(0.76–2.65) p>0.05 RM=0.87(0.41–1.87) p>0.05 | 25(31%) | >0.05(1.19) | >0.05 (1.44) | DM=1.47(0.78–2.74) p>0.05 RM=1.2(0.6–2.55) p>0.05 |
| AC | 38(41%) | 41(51%) | >0.05(1.31) | 38(46%) | >0.05(0.67) | ||||
| CC | 18(20%) | 14(18%) | >0.05(0.35) | 19(23%) | >0.05(0.58) | ||||
| Allele | Female Controls | Female POAG | p (χ2) | OR (95% CI) | Female PCAG | p (χ2) | OR (95% CI) | ||
| A | 110(60%) | 91(57%) | >0.05(0.3) | 1.13(0.73–1.73) p>0.05 | 88(54%) | >0.05(1.33) | 1.3(0.84–1.96) p>0.05 | ||
| C | 74(40%) | 69(43%) | 76(46%) |